Cyclo Therapeutics (NASDAQ:CYTH) Stock Price Up 3.8%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH)’s share price rose 3.8% during mid-day trading on Friday . The stock traded as high as $1.42 and last traded at $1.35. Approximately 28,969 shares changed hands during trading, a decline of 67% from the average daily volume of 87,838 shares. The stock had previously closed at $1.30.

Wall Street Analyst Weigh In

CYTH has been the topic of several recent research reports. HC Wainwright assumed coverage on shares of Cyclo Therapeutics in a research report on Wednesday, May 1st. They set a “buy” rating and a $3.00 target price on the stock. Ascendiant Capital Markets began coverage on shares of Cyclo Therapeutics in a research note on Monday, April 22nd. They issued a “buy” rating and a $2.60 target price for the company.

Cyclo Therapeutics Trading Up 3.8 %

The stock’s fifty day moving average is $1.39 and its two-hundred day moving average is $1.51. The company has a market capitalization of $38.64 million, a PE ratio of -1.35 and a beta of -0.18.

Cyclo Therapeutics (NASDAQ:CYTH) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.44 million. Cyclo Therapeutics had a negative net margin of 1,720.76% and a negative return on equity of 2,741.89%. As a group, analysts anticipate that Cyclo Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund V Management LLC purchased a new position in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics accounts for about 80.8% of Founders Fund V Management LLC’s portfolio, making the stock its biggest position. Founders Fund V Management LLC owned about 2.11% of Cyclo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 68.55% of the company’s stock.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.